Updated on 2026/04/08

写真a

 
Shuntaro Ikegawa
 
Organization
Scheduled update Assistant Professor
Position
Assistant Professor
Contact information
メールアドレス
External link

Research Interests

  • Regulatory T-cells

  • Graft-versus-host disease

  • CAR-T cell therapy

  • Allogeneic stem cell transplantation

Education

  • Okayama University   大学院医歯薬学総合研究科  

    2016.4 - 2020.3

      More details

  • Kagoshima University   医学部  

    2004.4 - 2010.3

      More details

Research History

  • Okayama University Hospital   血液内科   Assistant Professor

    2025.8

      More details

  • Dana-Farber Cancer Institute

    2021.2 - 2025.7

      More details

  • Okayama University Hospital   血液・腫瘍内科

    2016.4 - 2017.3

      More details

  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Komagome Hospital   血液内科

    2012.4 - 2016.3

      More details

  • 愛媛県立中央病院   初期研修医

    2010.4 - 2012.3

      More details

 

Papers

  • Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy

    Wataru Kitamura, Noboru Asada, Shuntaro Ikegawa, Hideaki Fujiwara, Chihiro Kamoi, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

    Internal Medicine   2024.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.2556-23

    researchmap

  • Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch

    Takumi Kondo, Keiko Fujii, Nobuharu Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2023.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/trf.17450

    researchmap

  • Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide

    Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Miki Iwamoto, Midori Filiz Nishimura, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken-ichi Matsuoka

    JCI Insight   2023.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1172/jci.insight.162180

    researchmap

  • Low hematocrit reduces the efficiency of CD34+ cell collection when using the Spectra Optia continuous mononuclear cell collection procedure

    Takumi Kondo, Nobuharu Fujii, Keiko Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2022.5

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/trf.16856

    researchmap

  • A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.

    Ryo Mizuta, Yoshihiro Otani, Kentaro Fujii, Atsuhito Uneda, Joji Ishida, Takehiro Tanaka, Shuntaro Ikegawa, Nobuharu Fujii, Yoshinobu Maeda, Isao Date

    NMC case report journal   9   275 - 280   2022

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Although high-dose methotrexate (HD-MTX) is the standard therapy for primary central nervous system lymphoma (PCNSL), the prognosis remains poor. Because 90% of PCNSL is diffuse large B-cell lymphoma (DLBCL), chimeric antigen receptor (CAR)-T cell therapy is expected to be beneficial. However, there are limited reports on CAR-T cell therapy for PCNSL because of the concern of neurotoxicity. Here, we report a case of relapsed PCNSL treated with anti-CD19 CAR-T cell therapy. A 40-year-old woman presenting with visual disturbance in her left eye was initially diagnosed with bilateral uveitis. Her histological diagnosis was DLBCL, and she was positive for CD19. Although she received chemotherapy including HD-MTX, the tumor relapsed in her right occipital lobe. She underwent remission induction therapy and then anti-CD19 CAR-T cell therapy. Cytokine release syndrome (CRS) grade 2 occurred, but there were no complications of CAR-T cell-related encephalopathy syndrome (CRES). She has achieved complete response for more than 1 year. Anti-CD19 CAR-T cell therapy is a revolutionary immunotherapy for treating relapsed or refractory (R/R) B lineage malignancies. Although there are concerns regarding CRS and CRES in central nervous system lymphoma, the use of anti-CD19 CAR-T cells to treat R/R PCNSL is safe and feasible.

    DOI: 10.2176/jns-nmc.2022-0134

    PubMed

    researchmap

  • Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.

    Yuta Yamada, Shuntaro Ikegawa, Yuho Najima, Yuya Atsuta, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Satoshi Kaito, Ryohei Nagata, Yuma Noguchi, Atsushi Marumo, Junichi Mukae, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Takeshi Kobayashi, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki

    International journal of hematology   115 ( 2 )   244 - 254   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Fludarabine with intravenous busulfan (6.4 mg/kg; FB2) and fludarabine with intermediate-dose melphalan (140 mg/m2; FM140) are the most widely used reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation. FM140 generally has a lower relapse rate and higher non-relapse mortality (NRM), resulting in overall survival (OS) comparable to that seen with FB2. To evaluate the effect of reducing the melphalan dose, we retrospectively compared transplant outcomes in 156 patients who received FB2 (n = 103) or FM80 (n = 53) at our center (median age: 63 years; range 27-72 years). All patients received 4-Gy total body irradiation. Three-year OS, the cumulative incidence of relapse, and NRM were comparable between groups (FB2 vs. FM80, 58% vs. 47%, p = 0.24; 30% vs. 36%, p = 0.57; 17% vs. 21%, p = 0.44, respectively). There was no significant difference in the cumulative incidence of graft-versus-host disease (GVHD) at day 100, chronic GVHD at 3 years, or the 3-year GVHD-free/relapse-free survival rate. In the high-risk disease group, patients receiving FM80 tended to have lower 3-year OS (FB2 vs. FM80, 48% vs. 17%, p = 0.06). In summary, transplant outcomes following FB2 or FM80 were comparable except in patients with high-risk disease.

    DOI: 10.1007/s12185-021-03233-4

    PubMed

    researchmap

  • Donor Treg expansion by liposomal α‐galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft‐versus‐host disease Reviewed International journal

    Hiroyuki Sugiura, Ken‐ichi Matsuoka, Takuya Fukumi, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Yusuke Meguri, Miki Iwamoto, Yasuhisa Sando, Makoto Nakamura, Tomohiro Toji, Yasuyuki Ishii, Yoshinobu Maeda

    Immunity, Inflammation and Disease   9 ( 3 )   721 - 733   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    BACKGROUND AND AIM: Chronic graft-versus-host disease (cGVHD) is a major cause of nonrelapse morbidity and mortality following hematopoietic stem cell transplantation (HSCT). α-Galactosylceramide (α-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner. Stimulation of iNKT cells by α-GC leads to the production of not only immune-stimulatory cytokines but also immune-regulatory cytokines followed by regulatory T-cell (Treg) expansion in vivo. METHODS: We investigated the effect of iNKT stimulation by liposomal α-GC just after transplant on the subsequent immune reconstitution and the development of sclerodermatous cGVHD. RESULTS: Our study showed that multiple administrations of liposomal α-GC modulated both host- and donor-derived iNKT cell homeostasis and induced an early expansion of donor Tregs. We also demonstrated that the immune modulation of the acute phase was followed by the decreased levels of CXCL13 in plasma and follicular helper T cells in lymph nodes, which inhibited germinal center formation, resulting in the efficient prevention of sclerodermatous cGVHD. CONCLUSIONS: These data demonstrated an important coordination of T- and B-cell immunity in the pathogenesis of cGVHD and may provide a novel clinical strategy for the induction of immune tolerance after allogeneic HSCT.

    DOI: 10.1002/iid3.425

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/iid3.425

  • Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Reviewed International journal

    Makoto Nakamura, Yusuke Meguri, Shuntaro Ikegawa, Takumi Kondo, Yuichi Sumii, Takuya Fukumi, Miki Iwamoto, Yasuhisa Sando, Hiroyuki Sugiura, Noboru Asada, Daisuke Ennishi, Shuta Tomida, Emi Fukuda-Kawaguchi, Yasuyuki Ishii, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Scientific reports   11 ( 1 )   13125 - 13125   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune intensity after PTCy for each patient's condition have not been well studied. Here, we investigated the effects of reducing the dose of PTCy followed by α-galactosylceramide (α-GC), a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect. In a murine haploidentical HSCT model, insufficient GVHD prevention after reduced-dose PTCy was efficiently compensated for by multiple administrations of α-GC. The ligand treatment maintained the enhanced GVL effect after reduced-dose PTCy. Phenotypic analyses revealed that donor-derived B cells presented the ligand and induced preferential skewing to the NKT2 phenotype rather than the NKT1 phenotype, which was followed by the early recovery of all T cell subsets, especially CD4+Foxp3+ regulatory T cells. These studies indicate that α-GC administration soon after reduced-dose PTCy restores GVHD-preventing activity and maintains the GVL effect, which is enhanced by reducing the dose of PTCy. Our results provide important information for the development of a novel strategy to optimize PTCy-based transplantation, particularly in patients with a potential relapse risk.

    DOI: 10.1038/s41598-021-92526-z

    PubMed

    researchmap

  • Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells

    Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Yuichi Sumii, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Miki Iwamoto, Yoshinobu Maeda, Ken-ichi Matsuoka

    ImmunoHorizons   2021.6

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.4049/immunohorizons.2100042

    researchmap

  • Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab

    Shuntaro Ikegawa, Yusuke Meguri, Kentaro Mizuhara, Takuya Fukumi, Hiroki Kobayashi, Yuichi Sumii, Takumi Kondo, Yasuhisa Sando, Miki Iwamoto, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yuka Fujisawa, Toshi Imai, Yoshinobu Maeda, Ken-ichi Matsuoka

    Leukemia   2021.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1038/s41375-021-01167-8

    researchmap

  • 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy

    Yasuhisa Sando, Ken-ichi Matsuoka, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Atae Utsunomiya, Takashi Oka, Yoshinobu Maeda

    Scientific Reports   10 ( 1 )   2020.10

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1038/s41598-020-74174-x

    researchmap

  • Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease

    Miki Iwamoto, Shuntaro Ikegawa, Takumi Kondo, Yusuke Meguri, Makoto Nakamura, Yasuhisa Sando, Hiroyuki Sugiura, Yuichi Sumii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Misako Shibakura, Yoshinobu Maeda, Ken-ichi Matsuoka

    Bone Marrow Transplantation   2020.10

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1038/s41409-020-01100-0

    researchmap

  • PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade

    Shuntaro Ikegawa, Yusuke Meguri, Takumi Kondo, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Miki Iwamoto, Yoshinobu Maeda, Ken-ichi Matsuoka

    Blood Advances   2019.12

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1182/bloodadvances.2019000134

    researchmap

  • Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels.

    Sugiura H, Matsuoka KI, Sando Y, Meguri Y, Ikegawa S, Nakamura M, Iwamoto M, Yoshioka T, Asano T, Kondo E, Fujii K, Fujii N, Maeda Y

    Transfusion and Apheresis Science   2019.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transci.2019.05.011

    PubMed

    researchmap

  • Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome.

    Sugiura H, Matsuoka KI, Matsuda M, Ikegawa S, Inomata T, Kuroi T, Asano T, Yoshida S, Nishimori H, Fujii K, Fujii N, Maeda Y

    International journal of hematology   2019.5

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-019-02659-1

    PubMed

    researchmap

  • [Transfusion-associated circulatory overload with pulmonary alveolar hemorrhage following allogeneic bone marrow transplantation].

    Adachi H, Doki N, Hino Y, Senoo Y, Ikegawa S, Watanabe D, Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Haraguchi K, Kitahara Y, Ohashi K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   2019.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.60.296

    PubMed

    researchmap

  • Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.

    Harada K, Sekiya N, Ikegawa S, Sasaki S, Kobayashi T, Ohashi K

    International journal of hematology   2018.10

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-018-2544-x

    PubMed

    researchmap

  • Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation.

    Nakamura M, Fujii N, Shimizu K, Ikegawa S, Seike K, Inomata T, Sando Y, Fujii K, Nishimori H, Matsuoka KI, Morimatsu H, Maeda Y

    International journal of hematology   2018.9

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-018-2536-x

    PubMed

    researchmap

  • Neurolymphomatosis in the Cauda Equina Diagnosed by an Open Biopsy.

    Sasaki R, Ohta Y, Yamada Y, Tadokoro K, Takahashi Y, Sato K, Shang J, Takemoto M, Hishikawa N, Yamashita T, Yasuhara T, Date I, Ikegawa S, Fujii N, Abe K

    Internal medicine (Tokyo, Japan)   2018.8

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.1049-18

    PubMed

    researchmap

  • Progressive multifocal leukoencephalopathy after T‐cell replete HLA‐haploidentical transplantation with post‐transplantation cyclophosphamide graft‐versus‐host disease prophylaxis

    Shuntaro Ikegawa, Nobuharu Fujii, Koh Tadokoro, Kota Sato, Miki Iwamoto, Masayuki Matsuda, Tomoko Inomata, Hiroyuki Sugiura, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Ken‐ichi Matsuoka, Yoshinobu Maeda

    Transplant Infectious Disease   2018.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/tid.12850

    researchmap

  • Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.

    Ikegawa S, Matsuoka KI, Inomata T, Ikeda N, Sugiura H, Kuroi T, Asano T, Yoshida S, Nishimori H, Fujii N, Kondo E, Maeda Y, Tanimoto M

    International journal of hematology   2018.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-017-2398-7

    PubMed

    researchmap

  • Erythrocytosis after allogeneic hematopoietic stem cell transplantation.

    Hino Y, Doki N, Kurosawa S, Yamamoto K, Sakaguchi M, Harada K, Ikegawa S, Shingai N, Hattori K, Senoo Y, Igarashi A, Najima Y, Kobayashi T, Ohashi K

    Clinical transplantation   2017.2

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ctr.12918

    PubMed

    researchmap

  • Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia.

    Ikegawa S, Doki N, Kaito S, Kurosawa S, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Watanabe D, Hagino T, Yoshioka K, Watakabe K, Ohashi K

    Pathology oncology research : POR   2016.12

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12253-016-0162-6

    PubMed

    researchmap

  • Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

    Hattori K, Doki N, Kurosawa S, Hino Y, Yamamoto K, Sakaguchi M, Harada K, Ikegawa S, Shingai N, Senoo Y, Igarashi A, Najima Y, Kobayashi T, Ohashi K

    Annals of hematology   2016.10

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00277-016-2854-0

    PubMed

    researchmap

  • Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.

    Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, Mimura I, Morita H, Sugiyama D, Nishikawa H, Hattori M, Hino Y, Ikegawa S, Yamamoto K, Ohashi K

    Blood   2016.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1182/blood-2016-05-717652

    PubMed

    researchmap

  • Chronic myeloid leukemia relapsing ten years after allogenic bone marrow transplantation.

    Hino Y, Doki N, Yamamoto K, Senoo Y, Sasajima S, Sakaguchi M, Hattori K, Kaito S, Kurosawa S, Harada K, Ikegawa S, Watanabe D, Hagino T, Yoshioka K, Ohashi K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   2016.5

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.57.608

    PubMed

    researchmap

  • [Chronic myelogenous leukemia initially presenting with multiple subcutaneous tumors due to extramedullary hematopoiesis].

    Kurosawa S, Doki N, Kaito S, Sakaguchi M, Harada K, Hino Y, Yamamoto K, Ikegawa S, Yosioka K, Watanabe D, Senoo Y, Watakabe K, Hagino T, Igarashi A, Ohashi K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   2016.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.57.461

    PubMed

    researchmap

  • Clinical utility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematological disease.

    Harada K, Kurosawa S, Hino Y, Yamamoto K, Sakaguchi M, Ikegawa S, Hattori K, Igarashi A, Watakabe K, Senoo Y, Najima Y, Hagino T, Doki N, Ohashi K

    SpringerPlus   2016.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40064-016-2161-1

    PubMed

    researchmap

  • Donor cell leukemia with bone marrow necrosis.

    Ikegawa S, Najima Y, Sano N, Horiguchi SI, Kaito S, Kurosawa S, Sakaguchi M, Harada K, Hino Y, Yamamoto K, Senoo Y, Watanabe D, Yoshioka K, Ohashi K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   2016.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.57.2334

    PubMed

    researchmap

  • Retrospective analysis of clinical outcomes of the patients with chronic myeloid leukemia who stopped administration of tyrosine kinase inhibitors: a single institution experience.

    Senoo Y, Yoshioka K, Kaito S, Kurosawa S, Harada K, Yamamoto K, Hino Y, Sakaguchi M, Ikegawa S, Watanabe D, Watakabe K, Hagino T, Igarashi A, Ohashi K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   2016.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.57.2481

    PubMed

    researchmap

  • Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.

    Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Watanabe K, Igarashi A, Najima Y, Ohashi K

    Leukemia & lymphoma   2016.1

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/10428194.2015.1063148

    PubMed

    researchmap

  • Retrospective Evaluation of Incidence and Prognostic Factors for Stenotrophomonas Maltophilia Bacteremia Following Allogeneic Hematopoietic Stem Cell Transplantation Reviewed

    Kaito Harada, Noritaka Sekiya, Shugo Sasaki, Satoshi Kaito, Shuhei Kurosawa, Yutaro Hino, Masahiro Sakaguchi, Keita Yamamoto, Shuntaro Ikegawa, Kosuke Yoshioka, Kyoko Watakabe, Daisuke Watanabe, Yasushi Senoo, Yuho Najima, Takeshi Hagino, Takeshi Kobayashi, Noriko Doki, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English  

    Web of Science

    researchmap

  • CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.

    Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Hattori K, Igarashi A, Najima Y, Ohashi K

    Leukemia & lymphoma   2015.12

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/10428194.2015.1099644

    PubMed

    researchmap

  • Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.

    Oshikawa G, Yoshioka K, Takahashi Y, Shingai N, Ikegawa S, Kobayashil T, Doki N, Kakihana K, Ohashi K, Sakamaki H

    Pathology oncology research : POR   2015.4

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12253-015-9933-8

    PubMed

    researchmap

  • Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia.

    Ikegawa S, Doki N, Yamamoto K, Shingai N, Takahashi Y, Aoki J, Yoshioka K, Narukawa K, Ishida S, Igarashi A, Oshikawa G, Kobayashi T, Kakihana K, Ohashi K

    Leukemia & lymphoma   2014.11

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3109/10428194.2014.974044

    PubMed

    researchmap

  • [Discussion meeting on the daily practice of leukemia].

    Kizaki M, Nomura T, Ikegawa S, Takahashi N, Uchida N

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   2013.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/naika.102.1767

    PubMed

    researchmap

  • Hepatocellular carcinoma in a case of Wilson's disease treated with radiofrequency ablation therapy.

    Ikegawa S, Hiraoka A, Shimizu Y, Hidaka S, Tazuya N, Ichiryu M, Nakahara H, Tanabe A, Tanihira T, Hasebe A, Miyamoto Y, Ninomiya T, Hirooka M, Michitaka K

    Internal medicine (Tokyo, Japan)   2011.7

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.50.5203

    PubMed

    researchmap

▼display all

MISC

  • Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM Reviewed

    146 ( Supplement 1 )   5713   2025

     More details

  • Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation Reviewed

    144 ( Supplement 1 )   1041   2024

     More details

  • Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease Reviewed

    144 ( Supplement 1 )   379   2024

     More details

    Authorship:Lead author  

    researchmap

  • Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform Reviewed

    144 ( Supplement 1 )   149   2024

     More details

    Authorship:Lead author  

    researchmap

  • OA-06 Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform Reviewed

    23 ( Supplement 2 )   S4   2023

     More details

    Authorship:Lead author  

    researchmap

  • T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity, Reviewed

    Shuntaro Ikegawa, Adam S. Sperling, Michela Ansuinelli, Sarah Nikiforow, David Quinn, Dexiu Bu, Jennifer Mataraza, David Pearson, Lawrence Rispoli, Marc A Credi, Nina Orwitz, Yohei Arihara, Rao Prabhala, Lakshmi Bhavani Potluri, Carol Reynolds, Serena De Vita, Nikhil C Munshi, Jerome Ritz

    Blood   142 ( Supplement 1 )   3469   2023

     More details

    Authorship:Lead author  

    researchmap

  • Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). Reviewed

    41 ( 16_suppl )   8004   2023

     More details

  • Low Dose IL-2 Therapy in Patients with Chronic Gvhd Induces PD-1+treg That Are Highly Activated, Immune Suppressive, and Proapoptotic Reviewed

    28 ( Supplement )   S59 - S60   2022

     More details

    Authorship:Lead author  

    researchmap

  • Picture in Clinical Hematology(No.94) 慢性移植片対宿主病の経過中にみとめられた食道粘膜脱落病変

    阪口 正洋, 土岐 典子, 日野 裕太郎, 海渡 智史, 黒澤 修兵, 山本 圭太, 原田 介斗, 池川 俊太郎, 渡邉 大介, 萩野 剛史, 吉岡 康介, 渡壁 恭子, 五十嵐 愛子, 妹尾 寧, 名島 悠峰, 小林 武, 垣花 和彦, 坂巻 壽, 大橋 一輝

    臨床血液   57 ( 6 )   691 - 691   2016.6

  • 55歳以上の造血器悪性腫瘍に対する血縁者間HLA半合致移植の成績 単一施設20例の後方視的検討

    海渡 智史, 名島 悠峰, 山本 圭太, 池川 俊太郎, 渡邉 大介, 渡壁 恭子, 吉岡 康介, 五十嵐 愛子, 妹尾 寧, 小林 武, 土岐 典子, 垣花 和彦, 坂巻 壽, 大橋 一輝

    老年者造血器疾患研究会会誌   38th   29 - 32   2016

     More details

    Language:Japanese   Publisher:老年者造血器疾患研究会  

    J-GLOBAL

    researchmap

  • 打撲傷を契機に播種性緑膿菌感染症を呈した同種造血幹細胞移植後の1例

    阪口 正洋, 関谷 紀貴, 土岐 典子, 海渡 智史, 黒澤 修兵, 日野 裕太郎, 山本 圭太, 原田 介斗, 池川 俊太郎, 渡邉 大介, 萩野 剛史, 吉岡 康介, 渡壁 恭子, 妹尾 寧, 五十嵐 愛子, 名島 悠峰, 小林 武, 垣花 和彦, 坂巻 壽, 大橋 一輝

    臨床血液   57 ( 6 )   776 - 776   2016

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 血球貪食症候群を契機に発見された骨髄壊死を伴うドナー細胞白血病の1例

    池川 俊太郎, 名島 悠峰, 海渡 智史, 山本 圭太, 吉岡 康介, 渡邉 大介, 妹尾 寧, 渡壁 恭子, 五十嵐 愛子, 土岐 典子, 小林 武, 垣花 和彦, 坂巻 壽, 大橋 一輝

    臨床血液   56 ( 11 )   2365 - 2365   2015

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Clinical Impact of CD25 Expression of Leukemic Blasts on Subsequent Transplant Outcomes in Patients with Refractory or Relapsed Acute Myeloid Leukemia

    Shuntaro Ikegawa, Noriko Doki, Keita Yamamoto, Yutaro Hino, Kaito Harada, Naoki Shingai, Ken Watanabe, Yasushi Senoo, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • An Increase in Baseline Level of Urinary Liver-Type Fatty Acid-Binding Protein Linked with Poor Prognosis after Allogeneic Hematopoietic Stem Cell Transplantation

    Naoki Shingai, Taku Morito, Shuntaro Ikegawa, Keita Yamamoto, Yutaro Hino, Kaito Harada, Aiko Igarashi, Ken Watanabe, Yasushi Senoo, Yuho Najima, Noriko Doki, Takeshi Kobayashi, Kazuhiko Kakihana, Kazuteru Ohashi, Hisashi Sakamaki, Minoru Ando

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 当院における血縁者間末梢血幹細胞採取の後方視的検討

    五十嵐 愛子, 小林 武, 山本 圭太, 池川 俊太郎, 新谷 直樹, 遠矢 崇, 妹尾 寧, 渡邉 健, 名島 悠峰, 土岐 典子, 垣花 和彦, 原口 京子, 奥山 美樹, 大橋 一輝

    臨床血液   55 ( 9 )   1637 - 1637   2014

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

▼display all

Awards

  • American Society of Hematology Abstract Achievement Award

    2024  

     More details

  • American Society of Hematology Abstract Achievement Award

    2023  

     More details

  • 海外留学助成リサーチフェローシップ

    2022   上原記念生命科学財団  

     More details

  • American Society of Hematology Abstract Achievement Award

    2019  

     More details

  • JALSG Young Investigator Award

    2013  

     More details